Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
NCT ID: NCT00081796
Last Updated: 2008-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
438 participants
INTERVENTIONAL
2004-04-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
larotaxel (RPR109881, XRP9881)
capecitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have received previous treatment with anthracyclines (e.g., adriamycin, Doxorubicin) and taxanes (e.g., paclitaxel, docetaxel, Taxol®, Taxotere®) for your breast cancer and your doctor has determined that these treatment are no longer of benefit to you.
* Be at least 18 years of age.
* Not be taking other treatments for your cancer at the time you enter this trial.
* Not be pregnant.
Additionally, there are other criteria for study entry that a doctor participating in this study will need to review in detail with you and clinical assessments may need to be performed (e.g., lab tests, CT scans).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ICD CSD
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
Bakersfield, California, United States
Burbank, California, United States
Concord, California, United States
Fountain Valley, California, United States
Fresno, California, United States
Fullerton, California, United States
Gilroy, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Monterey Park, California, United States
Northridge, California, United States
Oxnard, California, United States
Pomona, California, United States
Porterville, California, United States
Redondo Beach, California, United States
San Diego, California, United States
San Francisco, California, United States
Santa Barbara, California, United States
Soquel, California, United States
Vista, California, United States
New London, Connecticut, United States
Newark, Delaware, United States
Fort Lauderdale, Florida, United States
Fort Lauderdale, Florida, United States
Gainsville, Florida, United States
Jacksonville, Florida, United States
Lake Worth, Florida, United States
Orlando, Florida, United States
West Palm Beach, Florida, United States
Lawrenceville, Georgia, United States
Macon, Georgia, United States
Marietta, Georgia, United States
Roswell, Georgia, United States
Centralia, Illinois, United States
Chicago, Illinois, United States
Peoria, Illinois, United States
Skokie, Illinois, United States
Fort Wayne, Indiana, United States
New Albany, Indiana, United States
Danville, Kentucky, United States
Hazard, Kentucky, United States
Lexington, Kentucky, United States
Lafayette, Louisiana, United States
Shreveport, Louisiana, United States
Annapolis, Maryland, United States
Baltimore, Maryland, United States
Saint Joseph, Michigan, United States
Southfield, Michigan, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
Hackensack, New Jersey, United States
Nyack, New York, United States
Utica, New York, United States
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Charlotte, North Carolina, United States
Greenville, North Carolina, United States
Raleigh, North Carolina, United States
Wilmington, North Carolina, United States
Winston-Salem, North Carolina, United States
Bismarck, North Dakota, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Cleveland, Ohio, United States
Worthington, Ohio, United States
Dunmore, Pennsylvania, United States
Hershey, Pennsylvania, United States
Kingston, Pennsylvania, United States
Kttaning, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Charleston, South Carolina, United States
Greenville, South Carolina, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Richardson, Texas, United States
Abingdon, Virginia, United States
Arlington, Virginia, United States
Kirkland, Washington, United States
Spokane, Washington, United States
Huntington, West Virginia, United States
Buenos Aires, , Argentina
Capital Federal, , Argentina
Santa Fe, , Argentina
Melbourne, , Australia
Perth, , Australia
St Leonards, , Australia
Sydney, , Australia
Bludesch, , Austria
Vienna, , Austria
Sorocaba, São Paulo, Brazil
São Paulo, , Brazil
St. John's, Newfoundland and Labrador, Canada
Lévis, Quebec, Canada
Québec, Quebec, Canada
Montreal, , Canada
Ontario, , Canada
Ottawa, , Canada
Québec, , Canada
Las Condes
Santiago, , Chile
Santiago, , Chile
Bogotá, , Colombia
Cali Valle, , Colombia
Medellín, , Colombia
Hradec Králové, , Czechia
Nora Ves Pod Plesi, , Czechia
Ostrava, , Czechia
Kemi, , Finland
Oulu, , Finland
Besançon, , France
Lyon, , France
Marseille, , France
Montpellier, , France
Nice, , France
Paris, , France
Saint-Cloud, , France
Saint-Herblain, , France
Aschaffenburg, , Germany
Berlin, , Germany
Frankfurt, , Germany
Halle, , Germany
Heidelberg, , Germany
Kiel, , Germany
Munchen Bayern, , Germany
Munich, , Germany
Oldenberg, , Germany
Budapest, , Hungary
Szeged, , Hungary
Ashkelon, , Israel
Beersheba, , Israel
Haifa, , Israel
Tel Aviv, , Israel
Tel Litwinsky, , Israel
Bologna, , Italy
Cuneo, , Italy
Largo Agostino Gemelli, , Italy
Livorno, , Italy
Modena, , Italy
Napoli, , Italy
Novara, , Italy
Palermo, , Italy
Pavia, , Italy
Sassari, , Italy
Mexico DF Distrio Federal, , Mexico
Tuluea Estand de Mexico, , Mexico
Auckland, , New Zealand
Christchurch, , New Zealand
Kracow, , Poland
Warsaw, , Poland
Porto, Porto District, Portugal
Beja, , Portugal
Coimbra, , Portugal
Lisbon, , Portugal
Bucharest, Bucharest, Romania
Cluj-Napoca, , Romania
Craiova, , Romania
Maribor, , Slovenia
Capetown, , South Africa
Durban, , South Africa
Johannesburg, , South Africa
Parktown, , South Africa
Pretoria, , South Africa
Gyeonggi-do, , South Korea
Seoul, , South Korea
Alicante, , Spain
Jaén, , Spain
Madrid, , Spain
Navarra, , Spain
Valencia, , Spain
Taipai, , Taiwan
Taoyuang, , Taiwan
Birmingham, Birmingham, United Kingdom
Cardiff, Carduff, United Kingdom
Bristol, , United Kingdom
Ipswich, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom
Nottingham, , United Kingdom
Surrey, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XRP9881B-3001
Identifier Type: -
Identifier Source: secondary_id
EFC6089
Identifier Type: -
Identifier Source: org_study_id
NCT00107406
Identifier Type: -
Identifier Source: nct_alias